78 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
. 65 (89%) patients had cytokine release syndrome (CRS), with the majority of CRS cases at grades 1 and 2, and 9 (12%) at grade 3 and no cases reported … at Grade 4 or 5. 64 (88%) patients had hematopoietic cytopenias and the majority (86%) of events were Grade 3 or higher. Less than 5% of patients
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
13 Sep 21
Other Events
7:08am
and neck, esophagogastric junction, bladder, and synovial sarcoma cancers -
- Majority of patients experienced antitumor activity with a disease … -generation cell therapy appears safe and demonstrated antitumor activity for a majority of patients across many cancer indications.”
Topline results
S-3ASR
ADAP
Adaptimmune Therapeutics Plc
12 Jul 18
Automatic shelf registration
4:30pm
without cause by an ordinary resolution (which is passed by a simple majority of those voting in person or by proxy at a general meeting) irrespective … of incorporation, directors may be removed from office, with or without cause, by a majority stockholder vote, though in the case of a corporation whose board
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
27 Oct 16
Entry into a Material Definitive Agreement
12:00am
shorter with each successive line of therapy. The majority of patients eventually have a relapse which cannot be further treated.
About Adaptimmune’s TCR
8-K
EX-99.1
3il837djy7u49
12 Nov 21
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
6:30am
424B5
fpo 6rmfuvqv0i0
1 Jun 20
Prospectus supplement for primary offering
6:06am
S-4/A
muwxl 181og
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
424B3
k3m 0t9x8wea5hu6oe
20 Apr 23
Prospectus supplement
4:32pm
424B5
2wur6k1j
2 Jun 20
Prospectus supplement for primary offering
5:05pm
S-4
6uy2yajz2e7dci
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
20-F
r0c52l91jp78k7y5l4nx
13 Oct 15
Annual report (foreign)
12:00am
424B5
8nznnfvjtp 4j2l1e7
21 Jan 20
Prospectus supplement for primary offering
5:21pm
424B5
anm kp3l2i1dp
22 Jan 20
Prospectus supplement for primary offering
5:31pm
DRS
hsehvwkfx
5 Feb 15
Draft registration statement
12:00am
8-K
z0suzrusvi1 4i
29 Apr 20
Other Events
8:06am